These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 23937295)

  • 1. Olfactory dysfunction in sporadic Parkinson's Disease and LRRK2 carriers.
    Johansen KK; Warø BJ; Aasly JO
    Acta Neurol Scand; 2014 May; 129(5):300-6. PubMed ID: 23937295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyposmia in G2019S LRRK2-related parkinsonism: clinical and pathologic data.
    Silveira-Moriyama L; Guedes LC; Kingsbury A; Ayling H; Shaw K; Barbosa ER; Bonifati V; Quinn NP; Abou-Sleiman P; Wood NW; Petrie A; Sampaio C; Ferreira JJ; Holton J; Revesz T; Lees AJ
    Neurology; 2008 Sep; 71(13):1021-6. PubMed ID: 18809839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olfactory heterogeneity in LRRK2 related Parkinsonism.
    Silveira-Moriyama L; Munhoz RP; de J Carvalho M; Raskin S; Rogaeva E; de C Aguiar P; Bressan RA; Felicio AC; Barsottini OG; Andrade LA; Chien HF; Bonifati V; Barbosa ER; Teive HA; Lees AJ
    Mov Disord; 2010 Dec; 25(16):2879-83. PubMed ID: 20818658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olfactory dysfunction in LRRK2 G2019S mutation carriers.
    Saunders-Pullman R; Stanley K; Wang C; San Luciano M; Shanker V; Hunt A; Severt L; Raymond D; Ozelius LJ; Lipton RB; Bressman SB
    Neurology; 2011 Jul; 77(4):319-24. PubMed ID: 21753159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olfactory deficits and cardiac 123I-MIBG in Parkinson's disease related to the LRRK2 R1441G and G2019S mutations.
    Ruiz-Martínez J; Gorostidi A; Goyenechea E; Alzualde A; Poza JJ; Rodríguez F; Bergareche A; Moreno F; López de Munain A; Martí Massó JF
    Mov Disord; 2011 Sep; 26(11):2026-31. PubMed ID: 21611983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive LRRK2 and GBA screening in Portuguese patients with Parkinson's disease: identification of a new family with the LRRK2 p.Arg1441His mutation and novel missense variants.
    Zhang L; Quadri M; Guedes LC; Coelho M; Valadas A; Mestre T; Lobo PP; Rosa MM; Simons E; Oostra BA; Ferreira JJ; Bonifati V
    Parkinsonism Relat Disord; 2013 Oct; 19(10):897-900. PubMed ID: 23726462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subclinical signs in LRRK2 mutation carriers.
    Johansen KK; White LR; Farrer MJ; Aasly JO
    Parkinsonism Relat Disord; 2011 Aug; 17(7):528-32. PubMed ID: 21641848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers.
    Marras C; Schüle B; Munhoz RP; Rogaeva E; Langston JW; Kasten M; Meaney C; Klein C; Wadia PM; Lim SY; Chuang RS; Zadikof C; Steeves T; Prakash KM; de Bie RM; Adeli G; Thomsen T; Johansen KK; Teive HA; Asante A; Reginold W; Lang AE
    Neurology; 2011 Jul; 77(4):325-33. PubMed ID: 21753163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers.
    Brockmann K; Gröger A; Di Santo A; Liepelt I; Schulte C; Klose U; Maetzler W; Hauser AK; Hilker R; Gomez-Mancilla B; Berg D; Gasser T
    Mov Disord; 2011 Nov; 26(13):2335-42. PubMed ID: 21989859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olfaction and imaging biomarkers in premotor LRRK2 G2019S-associated Parkinson disease.
    Sierra M; Sánchez-Juan P; Martínez-Rodríguez MI; González-Aramburu I; García-Gorostiaga I; Quirce MR; Palacio E; Carril JM; Berciano J; Combarros O; Infante J
    Neurology; 2013 Feb; 80(7):621-6. PubMed ID: 23325906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonmotor symptoms in LRRK2 G2019S associated Parkinson's disease.
    Gaig C; Vilas D; Infante J; Sierra M; García-Gorostiaga I; Buongiorno M; Ezquerra M; Martí MJ; Valldeoriola F; Aguilar M; Calopa M; Hernandez-Vara J; Tolosa E
    PLoS One; 2014; 9(10):e108982. PubMed ID: 25330404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A clinical, neuropsychological and olfactory evaluation of a large family with LRRK2 mutations.
    Lohmann E; Leclere L; De Anna F; Lesage S; Dubois B; Agid Y; Dürr A; Brice A;
    Parkinsonism Relat Disord; 2009 May; 15(4):273-6. PubMed ID: 18718805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect?
    Orr-Urtreger A; Shifrin C; Rozovski U; Rosner S; Bercovich D; Gurevich T; Yagev-More H; Bar-Shira A; Giladi N
    Neurology; 2007 Oct; 69(16):1595-602. PubMed ID: 17938369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSF Nrf2 and HSPA8 in Parkinson's disease patients with and without LRRK2 gene mutations.
    Loeffler DA; Smith LM; Coffey MP; Aasly JO; LeWitt PA
    J Neural Transm (Vienna); 2016 Mar; 123(3):179-87. PubMed ID: 26526034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.
    Yahalom G; Kaplan N; Vituri A; Cohen OS; Inzelberg R; Kozlova E; Korczyn AD; Rosset S; Friedman E; Hassin-Baer S
    Parkinsonism Relat Disord; 2012 Nov; 18(9):1039-41. PubMed ID: 22703868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.
    Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ
    Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.
    Illarioshkin SN; Shadrina MI; Slominsky PA; Bespalova EV; Zagorovskaya TB; Bagyeva GKh; Markova ED; Limborska SA; Ivanova-Smolenskaya IA
    Eur J Neurol; 2007 Apr; 14(4):413-7. PubMed ID: 17388990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study.
    Hulihan MM; Ishihara-Paul L; Kachergus J; Warren L; Amouri R; Elango R; Prinjha RK; Upmanyu R; Kefi M; Zouari M; Sassi SB; Yahmed SB; El Euch-Fayeche G; Matthews PM; Middleton LT; Gibson RA; Hentati F; Farrer MJ
    Lancet Neurol; 2008 Jul; 7(7):591-4. PubMed ID: 18539535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for LRRK2 mutations in patients with Parkinson's disease in Russia: identification of a novel LRRK2 variant.
    Pchelina SN; Yakimovskii AF; Emelyanov AK; Ivanova ON; Schwarzman AL; Singleton AB
    Eur J Neurol; 2008 Jul; 15(7):692-6. PubMed ID: 18435766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fall risk and gait in Parkinson's disease: the role of the LRRK2 G2019S mutation.
    Mirelman A; Heman T; Yasinovsky K; Thaler A; Gurevich T; Marder K; Bressman S; Bar-Shira A; Orr-Urtreger A; Giladi N; Hausdorff JM;
    Mov Disord; 2013 Oct; 28(12):1683-90. PubMed ID: 24123150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.